Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy
Status:
Withdrawn
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open label, investigator-initiated study to be done at Duke University
Medical Center to treat adult patients (ages 18-80) with chronic plaque psoriasis who have
failed Biologic Therapy with Apremilast 30 mg BID for 24 weeks. At the time of enrollment,
the patient must have received biologic therapy without achieving a response of "almost
clear" or "clear" according to PGA or has not responded with a 75% reduction of PASI score.
Once deemed eligible, subjects will return for a baseline visit and receive Apremilast
therapy and instructions. Subjects will be treated at weeks 0,4,8,12,16,20 and 24; subjects
will be evaluated 28 days after last dose of Apremilast for safety and efficacy.